BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/29/2016 11:06:00 AM | Browse: 1340 | Download: 1974
Publication Name World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID 19049
Country United Kingdom
ISSN 2150-5349 (online)
Open Access Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List Anet A Soubières and Andrew Poullis
Funding Agency and Grant Number
Corresponding Author Dr. Anet A Soubières, Department of Gastroenterology, St George’s Hospital, University of London, Blackshaw Road, Tooting, London SW17 0QT, United Kingdom. anet.soubieres@gmail.com
Key Words Biomarkers; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Indeterminate colitis
Core Tip There is no gold standard test in the diagnosis of inflammatory bowel disease (IBD). Physicians must take into account clinical, endoscopic, and radiologic as well as serologic and histologic evidence in order to correctly diagnose their patients. Endoscopic evaluation is not only expensive, but is uncomfortable for patients and not without significant risk such as perforation. The use of biomarkers to help in the diagnosis and sub classification of IBD is an expanding area. In this review we touch on those non-invasive markers currently in clinical use before focusing on those more novel tests, with the potential to be highly useful in both diagnosis and differentiation of IBD.
Publish Date 2016-01-29 11:06
Citation Soubières AA, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 41-50
URL http://www.wjgnet.com/2150-5349/full/v7/i1/41.htm
DOI http://dx.doi.org/10.4292/wjgpt.v7.i1.41
Full Article (PDF) WJGPT-7-41.pdf
Full Article (Word) WJGPT-7-41.doc